These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23968993)

  • 1. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
    Wood J; Sames L; Moore A; Ekins S
    Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From drug cost to drug price: steps and decisional processes].
    Bruyninckx M; Nourissier C
    Presse Med; 2012 May; 41 Suppl 1():S40-3. PubMed ID: 22487715
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 4. Crafting a robust business model for orphan drug development.
    Philippidis A
    Hum Gene Ther; 2011 Jul; 22(7):781-3. PubMed ID: 21756074
    [No Abstract]   [Full Text] [Related]  

  • 5. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases.
    Swinney DC
    Clin Pharmacol Ther; 2016 Oct; 100(4):339-41. PubMed ID: 27393380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New models for pharmaceutical innovation in low-income countries.
    Ardal C; Iversen JH; Myhr K
    Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2016-8. PubMed ID: 22016131
    [No Abstract]   [Full Text] [Related]  

  • 7. Rare lung disease and orphan drug development.
    Spagnolo P; du Bois RM; Cottin V
    Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cohorts and registers: Which public/private partnerships to choose?].
    Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
    Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of academic institutions in the development of drugs for rare and neglected diseases.
    Coles LD; Cloyd JC
    Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Big pharma moves from 'blockbusters' to 'niche busters'.
    Dolgin E
    Nat Med; 2010 Aug; 16(8):837. PubMed ID: 20689537
    [No Abstract]   [Full Text] [Related]  

  • 12. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Orphan drugs : New opportunities for the treatment of rare diseases].
    Beck M
    Internist (Berl); 2016 Nov; 57(11):1132-1138. PubMed ID: 27527064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Birgitte Volck.
    Nat Rev Drug Discov; 2017 May; 16(6):378-379. PubMed ID: 28559559
    [No Abstract]   [Full Text] [Related]  

  • 16. Financing drug discovery for orphan diseases.
    Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW
    Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncommon ventures launch to tackle uncommon diseases.
    Dolgin E
    Nat Med; 2013 Aug; 19(8):950-1. PubMed ID: 23921728
    [No Abstract]   [Full Text] [Related]  

  • 19. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.